Biocon FY26: Growth Momentum and Margin Improvement Ahead

Ashwin Thakker

— 1 min read

Key Facts on Outlook:

  • Sales Outlook: Biocon anticipates accelerated growth across Biosimilars, CRDMO, and Generics segments in FY26. Generics specifically targets double-digit growth for the full year, propelled by multiple planned product launches. Biosimilars are set to build momentum through recent approvals and market penetration of products like Yesintek, Aspart, and Denosumab.
  • Margin Outlook: The company expects improving EBITDA margins, particularly in its Biosimilars business, driven by operating leverage and the increasing scale from new product launches. Gross margins for Biologics have held steady, with a positive trend in controlling operating expenses.

Biocon commenced FY26 on a strong note, signaling robust future performance. The Q1 earnings call highlighted the company's optimistic outlook for accelerated growth across its Biosimilars, CRDMO, and Generics segments. Strategic launches and operational efficiencies are set to drive both sales expansion and margin improvement in the coming quarters.

Unpacking Biocon's Growth Trajectory

Biocon is strategically positioned for growth, driven by an impressive pipeline and recent market entries. The company launched biosimilar Aflibercept in Canada, marking its tenth global biosimilar. Approvals for biosimilar Denosumab in Europe and the U.K. are also significant. In the U.S., the interchangeable rapid-acting insulin analogue, Aspart, and biosimilar Ustekinumab (Yesintek) are gaining strong formulary coverage and market traction. Management anticipates these new products, along with expanded manufacturing capabilities, will significantly fuel revenue growth.

Strengthening Margins and Balance Sheet

The company's commitment to improved profitability is evident. Biosimilars gross margins held steady, and operating expenses as a percentage of revenue are showing an improving trend. Management stated,

We are starting to see margins improvement as we go forward.

Core EBITDA saw an 11% year-on-year growth in Q1 FY26. A stronger balance sheet post-QIP and bond issuance means the interest burden is expected to reduce from Q2 FY26, directly benefiting the bottom line and enhancing overall financial resilience and financial flexibility.

Biocon's Q1 FY26 earnings call painted a clear picture of a company poised for sustained growth. Through strategic product launches, expanding market access, and disciplined financial management, Biocon is setting the stage for accelerated revenue expansion and enhanced profitability in the current fiscal year and beyond. The outlook remains firmly focused on capitalizing on new opportunities while strengthening core operations.

Read more